التفاصيل البيبلوغرافية
| العنوان: |
FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. |
| المؤلفون: |
Uson Junior, Pedro Luiz Serrano, DeLeon, Thomas T., Bogenberger, James M., Pai, Rish K., Kosiorek, Heidi E., Yin, Jun, Ahn, Daniel H., Sonbol, Mohammad Bassam, Bekaii-Saab, Tanios, Mansfield, Aaron S., Buetow, Kenneth, Gores, Gregory J., Smoot, Rory, Vasmatzis, George, Kipp, Benjamin R., Mahipal, Amit, Baker, Alexander T., Babiker, Hani, Barro, Oumar, Dumbauld, Chelsae |
| المصدر: |
Digestive Diseases & Sciences; Aug2022, Vol. 67 Issue 8, p3797-3805, 9p |
| مصطلحات موضوعية: |
PROTEIN expression, CHOLANGIOCARCINOMA, IMMUNOHISTOCHEMISTRY, PROGRESSION-free survival, OVERALL survival |
| مستخلص: |
Background: FGFR2 genomic alterations are observed in 10–20% of cholangiocarcinoma (CCA). Although FGFR2 fusions are an important actionable target, FGFR2 protein expression has not been thoroughly characterized. Aims: To evaluate FGFR2 protein expression in cholangiocarcinoma harboring FGFR2 genomic alterations. Methods: FGFR2 protein expression was evaluated in 99 CCA cases with two different antibodies. FGFR2 genomic alterations were confirmed via next-generating sequencing (NGS) or FISH. Primary objective was to determine the specificity and sensitivity of FGFR2 immunohistochemistry staining for detecting FGFR2 genomic alterations. Secondary objectives included overall FGFR2 immunohistochemistry staining in CCA patients, and evaluation of whether FGFR2 expression correlates with clinical outcomes including overall survival (OS), progression-free survival (PFS), and time-to-tumor recurrence (TTR). Results: Immunohistochemistry staining with two antibodies against FGFR2, FPR2-D, and clone 98706 showed high accuracy (78.7% and 91.9%) and specificity (82.9% and 97.7%), and moderate sensitivity (53.9% and 57.1%), respectively, when compared with the standard methods for detecting FGFR2 genomic alterations. In a median follow-up of 72 months, there were no statistically significant differences in OS, PFS, and TTR, for patients with positive or negative FGFR2 staining. Conclusion: FGFR2 protein expression by immunohistochemistry has high specificity and therefore could be used to imply the presence of FGFR2 genomic alterations in the context of a positive test. In the case of a negative test, NGS or FISH would be necessary to ascertain cases with FGFR2 genomic alterations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Digestive Diseases & Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
